Default: Immunotherapy

ISSN: 1750-743X

Journal Home

Journal Guideline

Immunotherapy Q2 Unclaimed

Taylor and Francis Ltd. United Kingdom
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Immunotherapy is a journal indexed in SJR in Immunology and Immunology and Allergy with an H index of 65. It has an SJR impact factor of 0,69 and it has a best quartile of Q2. It has an SJR impact factor of 0,69.

Immunotherapy focuses its scope in these topics and keywords: immunotherapy, model, immune, cells, cell, t, adoptive, fate, fab’neutralize, expressing, ...

Type: Journal

Type of Copyright:

Languages:

Open Access Policy:

Type of publications:

Publication frecuency: -

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

Immunotherapy

0,69

SJR Impact factor

65

H Index

141

Total Docs (Last Year)

419

Total Docs (3 years)

6537

Total Refs

1015

Total Cites (3 years)

398

Citable Docs (3 years)

2.46

Cites/Doc (2 years)

46.36

Ref/Doc

Comments

No comments ... Be the first to comment!

Aims and Scope


immunotherapy, model, immune, cells, cell, t, adoptive, fate, fab’neutralize, expressing, expanded, hn, humanized, immunityextracorporeal, immunological, infection, influenza, inhibitors, exercise, enzymes, antigen, aspects, avian, blood, cancer, chimeric, chronic, control, cord, cultures, diseases, diseasesphingolipid, ebvassociated,



Best articles by citations

Melanoma: a prototype of cancer-testis antigen-expressing malignancies

View more

Pentapeptide commonality betweenCorynebacterium diphtheriaetoxin and theHomo sapiensproteome

View more

Modulation of cancer-specific immune responses by amino acid degrading enzymes

View more

Biologics in spondyloarthritis: TNFa inhibitors and other agents

View more

Epstein-Barr virus-specific adoptive immunotherapy: a new horizon for multiple sclerosis treatment?

View more

Adjunct oral immunotherapy in patients with re-treated, multidrug-resistant or HIV-coinfected TB

View more

Bapineuzumab: anti-beta-amyloid monoclonal antibodies for the treatment of Alzheimer's disease

View more

Research Highlights

View more

Anti-CD 19 and anti-CD 20 CAR-modified T cells for B-cell malignancies: a systematic review and meta-analysis

View more

Targeting targeted therapies

View more

gammad T cell-based anticancer immunotherapy: progress and possibilities

View more

Does clinical protection persist after food allergen oral immunotherapy?

View more
SHOW MORE ARTICLES

Invariant NK T cells: potential for immunotherapeutic targeting with glycolipid antigens

View more

Research Highlights: Immunotherapy to overcome lung tumor cell-induced escape from immunosurveillance

View more

Strategies to improve BCG vaccine efficacy

View more

Could targeting secretory leukocyte protease inhibitor be an effective therapeutic option to prevent infections in acute liver failure?

View more

Carboplatin hypersensitivity: evaluation and successful desensitization protocol

View more

Could targeting T-helper cells aid the development of effective cancer vaccines?

View more

Palmoplantar pustular psoriasis induced by adalimumab: a case report and literature review

View more

Cryptococcus neoformansgalactoxylomannan is a potent negative immunomodulator, inspiring new approaches in anti-inflammatory immunotherapy

View more

Production of anti-CD3/28 expanded CD4+ T lymphocytes from HIV-infected patients with different degrees of disease progression

View more

Scancell's vaccine SCIB1 could help to prevent recurrence of melanoma

View more

Development of a new tuberculosis vaccine: is there value in the mucosal approach?

View more

A Phase I clinical trial with subcutaneous immunotherapy vaccine of Timothy grass pollen extract according to EMA guidelines

View more

FAQS